Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Capital Employed: 2011-2025

Historic Return on Capital Employed for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Sep 2025 value amounting to -0.44%.

  • Lineage Cell Therapeutics' Return on Capital Employed fell 17.00% to -0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.44%, marking a year-over-year decrease of 17.00%. This contributed to the annual value of -0.23% for FY2024, which is 3.00% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Return on Capital Employed stood at -0.44%, which was down 11.81% from -0.39% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Capital Employed ranged from a high of -0.21% in Q4 2022 and a low of -0.47% during Q4 2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Return on Capital Employed value was -0.27% (recorded in 2023), while the average stood at -0.28%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first declined by 19bps in 2021, then rose by 26bps in 2022.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Return on Capital Employed stood at -0.47% in 2021, then climbed by 26bps to -0.21% in 2022, then dropped by 8bps to -0.29% in 2023, then grew by 5bps to -0.24% in 2024, then decreased by 17bps to -0.44% in 2025.
  • Its last three reported values are -0.44% in Q3 2025, -0.39% for Q2 2025, and -0.21% during Q1 2025.